GL1X · GenesisL1 explorer

MolNFT v1 · #26619 · protein

Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes

1WUT · Glycogen phosphorylase, muscle form: “Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes”. X-ray diffraction, 2 ligands (PLP, BN2), 13 pockets (best druggability 0.85). MolNFT v1 #26619…

PDB
1WUT
Type
protein
Length
816 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Glycogen phosphorylase, muscle form
EC
2.4.1.1
UniProt
P00489
Ligands
PLP, BN2
Pockets
13 · best druggability 0.85

Structure

x-ray diffraction · 1 distinct chain · 51% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AGlycogen phosphorylase, muscle form (EC 2.4.1.1)protein81651% helix, 15% strandP00489

Ligands and binding sites

  • PLP · Pyridoxal-5'-phosphate · ligand · chains A
  • BN2 · 7-[2,6-dichloro-4-({[(2-chlorobenzoyl)amino]carbonyl}amino)phenoxy]heptanoic acid · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

13 pockets found on a 1 Å grid, 5 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12960.850.9655PLP
21500.790.9642empty
32910.700.8533empty
41750.530.7926empty
51140.520.8120empty

Modifications

Observed in the structure: 1 cofactor (pyridoxal phosphate Schiff base).

Compared structures

  • 1WUT · Acyl Ureas as Human Liver Glycogen Phosphorylase Inhibitors for the Treatment of Type 2… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.